جست‌وجوی استاد و پژوهشگر

John McGrathمشاهده پروفایل

استاد

• Environmental Microbiology
• Biogeochemistry
• Wastewater Treatment
• +۵ مورد دیگر

John McGrath is Professor of Environmental Microbiology at Queen's University Belfast's School of Biological Sciences, and Director of the Irish Nutrient Sustainability Platform. He holds affiliations with the Institute for Global Food Security and Research Centre in Sustainable Energy. With a PhD supervision record of 15 completed and 12 ongoing doctoral students, he leads research in waste valorization and pathogen control. His research spans: Biogeochemical cycling of phosphorus/nitrogen in aquatic/terrestrial systems Metagenomic surveillance of pathogens (SARS-CoV-2, RSV, antimicrobial resistance) Development of biological/chemical waste treatment technologies Microbial ecology of anaerobic digestion systems Novel disinfection methods for ESKAPE pathogens Publications demonstrate strong focus on wastewater-based epidemiology (33% of recent articles), microbial phosphorus metabolism (27%), and pathogen genomics (20%). Research consistently integrates molecular biology with environmental engineering solutions. Current projects include: IMMACULATE: Sustainable mass spectrometry applications Irish Nutrient Platform development Phosphorus recovery technologies from wastewater Novel sorbents for nitrogen removal Leads cross-disciplinary teams at the Environmental Microbiology Lab, collaborating internationally on wastewater surveillance initiatives and microbial resource recovery projects.

• Microbiome
• Alzheimer's Disease
• Emergency Medicine
• +۴ مورد دیگر

John Haran, MD, PhD, is an Associate Professor of Emergency Medicine at UMass Chan Medical School's T.H. Chan School of Medicine, with cross-appointments in Microbiology and Biomedical Sciences. His research focuses on the microbiota-gut-brain axis and drug-resistant pathogens , particularly in relation to Alzheimer's disease , long-COVID , and post-traumatic neurological disorders . He leads NIH-funded studies on gut microbiome-immune-cognition interactions in aging populations and directs the Center for Microbiome Research's antimicrobial stewardship initiatives to reduce hospital-acquired infections. Education : BS in Biochemistry & Biophysics (Rensselaer Polytechnic Institute), MD and PhD in Biomedical Sciences (University of Massachusetts Medical School) Appointments : Associate Professor of Emergency Medicine, Associate Professor in Microbiology & Physiological Systems, Associate Clinical Director of the Center for Microbiome Research His research spans three core domains : 1. Microbiota-gut-brain axis - linking dysbiosis to Alzheimer's progression, long-COVID, and post-trauma cognition 2. Antimicrobial stewardship - reducing C. difficile and MDR transmission in hospitals and nursing homes 3. Neuroimmune trauma - mapping neural circuits associated with PTSD and depression via AURORA study's multimodal data Key trends in his publications include: - 2023-2025: machine learning applications for PTSD prediction - 2021-2025: gut-brain axis studies connecting microbial metabolites to brain function - 2018-2025: antibiotic misuse analyses in emergency settings Through the Antimicrobial Stewardship Taskforce , he implemented protocols reducing vancomycin overuse for skin infections. His research clinic enrolls longitudinal cohorts of elders with cognitive issues to develop microbiome-targeted therapies, and he collaborates with CDC on healthcare worker infection risks during pandemics.

Kelly R. Revelesمشاهده پروفایل

دانشیار

• Healthcare-associated infections
• Clostridioides difficile infections
• Gut microbiome
• +۵ مورد دیگر

Kelly R. Reveles is an Associate Professor at The University of Texas at Austin College of Pharmacy and an Adjunct Associate Professor at UT Health San Antonio School of Medicine. She earned her Pharm.D. (2010) and dual-Ph.D. in Translational Science (2014) from UT Austin and UT Health Science Center San Antonio. Her research focuses on reducing healthcare-associated infections, particularly Clostridioides difficile , through translational strategies spanning microbiome analysis, clinical trials, and pharmacoepidemiology. She leads NIH-funded studies including a $3.4M R01 grant investigating fecal microbiota transplantation’s impact on aging in marmosets. Education: Pharm.D., UT Austin College of Pharmacy & UT Health Science Center San Antonio (2010) Ph.D., Translational Science (UT Austin, UT Health San Antonio, and UT San Antonio) (2014) Key Roles: Graduate Advisor at UT Austin College of Pharmacy Co-leader, Pilot & Exploratory Studies Core at San Antonio Pepper Older Americans Independence Center Her research emphasizes multidisciplinary approaches to combat antimicrobial resistance, improve microbiome-targeted therapies, and address healthcare disparities. Major grants include NIH/NIA funding for microbiome-aging studies and AstraZeneca collaborations on cancer outcomes. Media highlights include New York Times coverage of her C. difficile work. Awards: Young Investigator Award (Society of Infectious Diseases Pharmacists, 2020) Ambulatory Care Paper of the Year (2021, 2019) Outstanding Faculty Advisor (2021) Grant Leadership: Principal Investigator: NIH/NIA Grant (2021-2024) studying microbiota-associated mice for aging research Co-PI: $3.4M NIH/NIA Grant (2020-2025) on microbiome-mediated therapies in marmosets Co-Investigator: Texas Targeted Opioid Response (2019-2024) Her work bridges clinical practice and public health, addressing urgent issues like hospital-acquired infections, opioid misuse, and antibiotic stewardship. She actively collaborates with academic, clinical, and industry partners to translate research into actionable healthcare solutions.

Christian Mengeمشاهده پروفایل

استاد

• Veterinary Microbiology
• Immunology
• Molecular Pathogenesis
• +۳ مورد دیگر

Prof. Dr. Christian Menge is a leading veterinary microbiologist and immunologist at the Institute of Molecular Pathogenesis (IMP), Justus-Liebig-Universität Gießen. He also serves as Head of IMP and Administrative Local Representative of the President at Friedrich-Loeffler-Institut (FLI) Jena. Academic Credentials: Dr. med. vet., Recognised Veterinarian Specialist in Microbiology and Immunology/Serology (German Chamber) Research Focus: Shiga toxin-producing E. coli (STEC), Coxiella burnetii, zoonotic bacterial pathogenesis, host-pathogen interactions in ruminants His work investigates airborne pathogen transmission (2017), Shiga toxin molecular biology (2020), and hypoxia-mediated immune evasion in bovine macrophages (2023). Recent publications highlight genomic host-specificity in E. coli (2023) and antimicrobial resistance in Camelid pathogens (2023). Scientific Recognition EBVS® European Specialist in Veterinary Microbiology

Frederik Emil Juulمشاهده پروفایل

پژوهشگر ارشد

• Microbiota Therapy
• Clostridioides difficile
• Colorectal Cancer
• +۴ مورد دیگر

Frederik Emil Juul is a Postdoctoral Fellow at the Department of Health Management and Health Economics, Faculty of Medicine, University of Oslo, and is affiliated with Oslo University Hospital. He is a key member of the Clinical Effectiveness research group where he conducts research on fecal microbiota transplantation, epidemiology, screening and surveillance, colon cancer, and gastrointestinal diseases. Dr. Juul also serves as a lecturer for medical students in the subject "KLoK" (Evidence based medicine, management and leadership, and Quality Improvement). Dr. Juul graduated as a doctor from the University of Oslo and defended his PhD thesis in 2023 on the effect and quality of endoscopic colon cancer screening. His clinical background includes work as a general practitioner and as a physician in specialization in internal medicine at Bærum Hospital. His primary research interests center on microbiota therapy , particularly for treating Clostridioides difficile infections, alongside colorectal cancer screening methodologies and epidemiological studies. Dr. Juul's research portfolio demonstrates a consistent focus on innovative gastrointestinal treatments, with particular emphasis on fecal microbiota transplantation as an alternative to traditional antibiotic therapy for C. difficile . His work spans from early-stage clinical trials to population-level epidemiological studies, reflecting a comprehensive approach to improving patient outcomes through evidence-based medicine. Recent publications show increasing focus on comparative effectiveness research, particularly in colorectal cancer screening modalities. Certificate of recognition as an early career investigator at Digestive Disease Week 2018 Best late-breaking abstract at UEG week 2024 for "Fecal microbiota transplant versus vancomycin for primary clostridioides difficile infection - a randomized non-inferiority trial" Dr. Juul is actively involved in teaching medical students and supervising research within the Clinical Effectiveness research group. His primary project is the COLONIZE clinical trial investigating fecal microbiota transplantation for primary C. difficile infections. He also contributes to research on microbiota therapy for irritable bowel syndrome and continues to publish on colorectal cancer screening effectiveness. As a core member of the Clinical Effectiveness research group at Oslo University Hospital, Dr. Juul collaborates with a multidisciplinary team of clinicians, researchers, and healthcare administrators to evaluate and improve clinical practices through rigorous scientific investigation, with particular attention to translating research findings into practical healthcare improvements.

• Immunology
• Microbiology
• Pharmacology
• +۵ مورد دیگر

Neil Foster is a Professor at Scotland's Rural College (SRUC) , focusing on immunology, microbiology, and veterinary science. His research explores host-pathogen interactions in livestock, particularly immune responses to bacterial infections like Salmonella and Clostridioides difficile . Key affiliations: Ferguson Building, Craibstone Estate, Aberdeen, UK Email: neil.foster@sruc.ac.uk Research interests span immunomodulation , zoonotic diseases , and molecular diagnostics . Recent work includes: DNA trap formation in porcine monocytes during C. difficile infection Role of microRNA in subclinical coccidiosis in broilers Salmonella persistence and carrier states in mice His publications emphasize applications in animal health and translational models for human disease.

Nuttada Panpradistمشاهده پروفایل

استادیار

• Biosensor Engineering
• Cell and Tissue Engineering
• Synthetic Biology
• +۷ مورد دیگر

Nuttada Panpradist is an Assistant Professor at The University of Texas at Austin in the Department of Biomedical Engineering. Her research focuses on developing sustainable diagnostic solutions to address global health disparities, with applications in infectious diseases, women’s health, and One Health. The Panpradist Lab (Panda Lab) integrates synthetic biology, biosensor engineering, and AI/ML to create rapid, accessible tools for clinical and resource-limited environments. Academic Rank: Assistant Professor University: The University of Texas at Austin Department: Biomedical Engineering Research interests include biosensor and diagnostic platform development, HIV/TB drug resistance detection, and equitable technology implementation. Her work employs isothermal molecular techniques, DNA logic circuits, and engineered phages to create low-cost diagnostics. Recent publications highlight her focus on LAMP-based assays, CRISPR-Cas integration, and point-of-care diagnostic systems. Key themes include infectious disease monitoring, resource-limited testing, and synthetic biology applications. Scientific awards : No awards explicitly mentioned. Advising and grants : No students or grants listed in available text. However, the lab emphasizes collaboration with stakeholders like Dell Medical School and international health ministries. Lab and team : The Panda Lab (est. Jan 2025) is an interdisciplinary research group at UT Austin BME, dedicated to transforming medical technology development through community engagement and global partnerships.

• Geriatrics
• Internal Medicine
• Cardiorespiratory Medicine
• +۷ مورد دیگر

Stefano Volpato is a Full Professor and Head of the Department of Medical Sciences at the University of Ferrara, Italy. He is based in the Section of Internal and Cardiorespiratory Medicine and operates from the Ferrara University Hospital, Room 1.35.19. His work bridges clinical medicine, geriatrics, and public health, with a strong focus on the health of older adults, particularly in hospital and long-term care settings. His research interests include geriatrics, internal medicine, frailty, nutritional status in the elderly, delirium, polypharmacy, and the impact of SARS-CoV-2 and vaccination in aging populations. He leads and collaborates on major multicenter studies such as the GeroCovid and APPROACH initiatives, emphasizing multidisciplinary approaches to improve care transitions and outcomes for older patients. The 15 most recent publications highlight a consistent focus on aging and vulnerability, with keywords spanning geriatrics, immunology, public health, and clinical medicine. Subfields include vaccine response in the elderly, frailty, nutritional risk, delirium, and long-term care epidemiology. His work frequently employs large datasets and collaborative networks to address real-world clinical challenges in geriatric populations. Scientific Awards: No awards listed in the provided text. As a senior academic and clinical leader, Stefano Volpato likely supervises PhD and medical students, though no formal list is provided. He has been involved in research grants related to the GeroCovid, APPROACH, and InCHIANTI studies, which focus on aging, vaccination, and multidisciplinary care. His leadership in these initiatives underscores his role in shaping geriatric research and policy in Italy. He is actively involved in research teams and networks such as the GeroCovid Observational and Vax initiatives, which bring together experts across institutions to study the impact of the pandemic on older adults. These collaborations aim to build robust long-term care health research infrastructure in Italy.

Roman A. Melnykمشاهده پروفایل

استاد

• Bacterial Pathogenesis
• Drug Discovery
• Structural Biology
• +۳ مورد دیگر

Roman A. Melnyk is a Professor in the Department of Biochemistry at the University of Toronto, with research focused on bacterial toxin pathogenesis and drug discovery. His work integrates chemical biology, molecular biophysics, and structural analysis to study bacterial toxins' mechanisms and develop therapeutic interventions. Research Interests: Drug discovery targeting bacterial toxins, biophysics of membrane protein transport, and engineering toxin-delivery platforms for non-cell-penetrant therapeutics. His studies address diseases caused by pathogens like Clostridium difficile and HIV-1, leveraging toxin biology for both inhibition and delivery applications. Scientific Awards: 2014 — Early Researcher Award, Ontario Ministry of Economic Development & Innovation Research Trends: Recent publications emphasize structural insights into toxin pores, small-molecule antivirulence strategies, and repurposing bacterial toxins for therapeutic delivery. Key subfields include C. difficile pathogenesis, HIV-1 reverse transcriptase inhibition, and computational modeling of toxin-host interactions. Labs & Collaborations: Melnyk leads a research lab at the University of Toronto, collaborating with institutions such as SickKids and Vanderbilt University. His work spans interdisciplinary areas including microbiology, pharmacology, and structural biology.

Thierry Jardeمشاهده پروفایل

عضو هیئت علمی

• Cancer Biology
• Stem Cell Research
• Organoid Models
• +۳ مورد دیگر

Thierry Jarde is a Senior Research Fellow in Anatomy & Developmental Biology at Monash University, specializing in cancer biology, stem cell research, and therapeutic development. He leads and collaborates on projects focused on organoid modeling, intestinal regeneration, and personalized medicine approaches for metastatic breast and colorectal cancers. Currently active in 7 research projects (2023–2028), including investigations into druggable vulnerabilities in cancer and fertility preservation post-immunotherapy. Recipient of 14 scientific awards, including the Best PhD award from the University of Auvergne (France) and multiple presentation/poster prizes. His research interests bridge molecular mechanisms (e.g., Wnt/ERBB3 signaling) and translational medicine. Key themes include tumor microenvironment dynamics, stem cell aging, and preclinical drug testing using organoid cultures. Publications span topics like organoid-based therapy, niche signaling in regeneration, and drug synergy in colorectal cancer. He actively participates in conferences, grant reviews, and educational workshops, such as the ‘Emerging technologies in organoid research’ symposium.

• Systems Biology
• Synthetic Biology
• Ubiquitin-Proteasome System
• +۵ مورد دیگر

Michael David Tyers is an Associate Professor at the Université de Montréal's Faculté de médecine and Département de médecine. He holds the Canada Research Chair in Systems and Synthetic Biology. His research focuses on understanding cellular networks' organization and control, particularly the ubiquitin-proteasome system's role in cell cycle regulation and cancer biology. Tyers leads the Systems and Synthetic Biology Unit at IRIC (Institut de recherche en immunologie et en cancérologie), developing chemical genetics and synthetic biology platforms for drug discovery and systems medicine. Education: PhD in Biochemistry (McMaster University), Postdoctoral training at Cold Spring Harbor Laboratory (NY). Previous roles include positions at the University of Toronto and University of Edinburgh. Research interests: Systems-level analysis of genetic networks, synthetic biology for antibiotic discovery, CRISPR-based genome-wide screens in human cancer cells, and chemical modulation of cellular pathways. His team combines proteomics, genetics, microscopy, and computational modeling to uncover therapeutic targets in cancer and infectious diseases. Key projects include developing synthetic biotic platforms for microbiome-based therapies, identifying genetic vulnerabilities in SARS-CoV-2, and discovering novel antibiotics using natural product-like compounds. Over 150 grants and collaborations span institutions like Génome Canada, NIH, and the Bill & Melinda Gates Foundation. Awards: Canada Research Chair (2018-2024), multiple grants from IRSC, CRSNG, and Apogée Canada.

Nikhil Paiمشاهده پروفایل

دانشیار بالینی

• Pediatric Gastroenterology
• Microbiome
• Nutritional Science
• +۷ مورد دیگر

Dr. Nikhil Pai is an Associate Clinical Professor of Pediatrics at McMaster University and a Staff Physician in the Division of Pediatric Gastroenterology at McMaster Children’s Hospital. He serves as Medical Lead of the Complex Pediatric Nutrition Service and Pediatric Intestinal Failure program. From July 2024, he will join the Perelman School of Medicine at the University of Pennsylvania as an Associate Professor of Pediatrics and Staff Physician at the Children’s Hospital of Philadelphia while maintaining a part-time Assistant Professor appointment at McMaster. Education: B.Sc, University of Western Ontario (2001–2004) M.D, McMaster University (2004–2007) Pediatrics Residency, Hospital for Sick Children/University of Toronto (2007–2011) Pediatric Gastroenterology Fellowship, Boston Children's Hospital/Harvard Medical School (2011–2014) Postdoctoral Research: Intestinal Microbiome, Massachusetts General Hospital/Harvard University (2012–2014) Research Focus: Dr. Pai specializes in pediatric gastroenterology with emphasis on nutritional science, microbial therapeutics, and host-microbiome interactions. His work includes pioneering clinical trials on fecal microbiota transplantation (FMT) for pediatric inflammatory bowel disease (IBD), and leadership of multicenter studies (PediFeTCh, PediCRaFT, FIND trials) examining microbial/nutritional interventions in ulcerative colitis, Crohn's disease, and fatty liver disease. His research bridges basic science and clinical applications in gut microbiome modulation. Publication Trends: His 15 most recent articles (2021–2025) focus on FMT clinical outcomes, urine metabolomics for IBD diagnosis, therapeutic nutrition, gut-brain axis disorders, and pediatric liver disease management, reflecting translational research bridging microbiome science and clinical gastroenterology. Awards: 2023 ASPEN Stanley J. Dudrick Research Award 2024 Canadian Nutrition Society Young Investigator Award Ontario Innovation Award Academic Activities: Dr. Pai mentors medical students, residents, and fellows, and has secured >$3.98M in research funding (CIHR/non-profit grants). He leads the Pai Lab and is Associate Member of McMaster's Farncombe Institute and MODR Centre. Administrative roles include co-chairing hospital nutrition committees and advising Health Canada on FMT therapeutics.

Andrew Hryckowianمشاهده پروفایل

استادیار

• Bacterial Pathogenesis
• Microbiome Science
• Bacteriophages
• +۳ مورد دیگر

Andrew Hryckowian serves as an Assistant Professor in the Department of Medical Microbiology and Immunology at the University of Wisconsin–Madison School of Medicine and Public Health. His research program investigates the molecular and genetic foundations of gut microbiome community dynamics, with direct clinical translation through collaborations at UW Hospitals and Clinics. The laboratory employs gnotobiotic mouse models, molecular genetics, and in vivo approaches to dissect host-microbe interactions in gastrointestinal infectious diseases. Education: BS, University of Pittsburgh, 2009 PhD, University of Wisconsin-Madison, 2014 Postdoctoral Fellowship, Stanford University, 2014-2020 Research Focus: Dr. Hryckowian's work centers on Bacterial Pathogenesis and Microbiome Science , specifically examining how butyrate metabolism , bacteriophage dynamics , and insertion sequence-driven evolution influence Clostridioides difficile infection and Group B Streptococcus colonization. His lab integrates metagenomics , molecular genetics , and clinical specimens to identify therapeutic targets for microbiome-related disorders, with emphasis on metabolite-mediated virulence regulation and phage-bacteria coevolution. Publication Trends: Recent publications (2021-2025) reveal a concentrated focus on C. difficile pathogenesis mechanisms, gut-resident pathobionts, and microbiome evolution. Key themes include the dual role of butyrate in infection dynamics, insertion sequence-mediated genomic plasticity in microbiota, and bacteriophage-host coadaptation. His work consistently bridges basic microbiology with clinical applications, particularly in developing diagnostic tools and probiotic interventions for infectious diseases. Scientific Awards: No awards documented in source materials Research Infrastructure: The laboratory operates within the Microbial Sciences Building, utilizing advanced gnotobiotic facilities and collaborating with clinical teams at UW Hospitals. Current efforts focus on translating molecular insights into microbiome management strategies, with ongoing projects examining phage therapy applications and metabolite-based therapeutics for gastrointestinal infections.

Bo Wangمشاهده پروفایل

استادیار

• Metabolomics
• NMR Spectroscopy
• Environmental Toxicology
• +۶ مورد دیگر

Dr. Bo Wang is an Assistant Professor in the Department of Chemistry and Chemical Engineering at Florida Institute of Technology's College of Engineering and Science. His research bridges analytical chemistry, data science, and biological applications with a focus on metabolomics methodologies and their implementation across environmental and human health domains. Dr. Wang's research interests center on computational methods development in metabolomics with applications spanning drug discovery of food compounds, environmental science, and cancer mechanism studies. His work includes instrumentation analysis using NMR and HPLC/MS on natural compound extractions and metabolomic profiling studies examining responses to various environmental exposures. A significant focus is finding links between cancer metabolomic profiling and plant extract compounds to identify synergistic combinations. He also investigates combinatorial effects of environmental toxins using NMR-based metabolomics approaches. His recent publications demonstrate strong trends in integrating metabolomics with microbiome analysis to study gut-brain axis mechanisms, environmental toxin effects on marine organisms, and metabolic responses to dietary interventions. The research increasingly incorporates machine learning approaches for metabolomics data interpretation and emphasizes sex-specific responses in metabolic studies. National Science Foundation (NSF) LEAPS-MPS: $248,613 for Artificial Intelligence Techniques for Automatic NMR Metabolomics Data Processing (2021-2025) Gulf of Mexico Alliance (GOMA): $200,000 for AI-Directed Tool Development for Pathogenic "Flesh-eating" Vibrio Bacteria Prediction and Control (2024-2027) National Institutes of Health (NIH) R01: $85,184 for Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimer's disease (2021-2026) NSF Collaborative Research: $168,690 for Therapeutic and Diagnostic System for Inflammatory Bowel Diseases (2023-2028) Dr. Wang actively mentors multiple PhD students including Julie Pollak (Metabolomics in human health), Moses Mayonu (Metabolomics data processing), Tammy Tran (Water pollutant treatment), and Saeedeh Babaee (Marine animal response to environmental toxins). His research group also includes several undergraduate students working on NMR-based metabolomics studies of milk products and tea extracts. The research is conducted through collaborations with institutions including University of South Florida, Florida State University, and Ohio University.

Ellen Ledwabaمشاهده پروفایل

مدرس

• One Health
• Water Quality
• Hygiene
• +۳ مورد دیگر

Dr. Ellen Ledwaba is a Lecturer in Microbiology at Rhodes University since 2023, with a focus on One Health-related water quality, bacterial pathogenesis, and antimicrobial resistance. Previously, she held post-doctoral and doctoral positions at the University of Venda and conducted pre-doctoral research at the University of Virginia. PhD in Microbiology (University of Venda, 2020) MSc in Microbiology (University of Venda, 2015) BSc in Microbiology (University of Limpopo, 2013) Her research bridges bacterial pathogenesis, host-pathogen interactions, and environmental health in low-resource settings. Publications highlight enteric pathogens (EPEC, Shigella, Campylobacter, C. difficile), co-infections, zinc deficiency impacts, and vaccine development using murine models. She explores transmission dynamics and hygiene factors in rural communities. Dr. Ledwaba's work spans diarrheal disease mechanisms, environmental microbiology, and translational approaches to public health challenges. Her collaborations with the University of Virginia and University of Venda emphasize global health and interdisciplinary research.